Company Information
Industry 制造业
Company Introduction 山东山大华特科技股份有限公司于2001年在深交所上市,股票代码000915,以环保和医药产业为主营业务.目前环保产业主要涉及电厂烟气脱硫服务、二氧化氯设备和产品的生产销售等业务,医药产业以儿童保健药品和心血管病、糖尿病、消化系统疾病治疗药及抗肿瘤药等药品的生产销售为主.公司通过了ISO9001:2000版国际质量管理体系认证,为中国环境保护产业骨干企业、山东省高新技术企业,先后承担多项国家"863"计划项目、山东省科技攻关项目,拥有国家专利和著作权二十余项、科研成果三十余项。 达因药业作为中国儿药行业的开拓者和引领者,自2007年以来,始终坚持“使千千万万中国儿童健康强壮”的企业使命,专注于儿童药品及儿童健康领域产品的研发与生产,形成了以“儿童保健和治疗领域”为核心的儿童健康产业布局。目前达因药业儿童药品主要包括伊可新维生素AD滴剂、伊D新、达因铁、达因钙、达因锌、口服补液盐散、小儿布洛芬栓、盐酸托莫西汀口服溶液及地氯雷他定口服液等。其中“伊可新”为中国驰名商标,多年来一直位居同类产品市场占有率第一。利用“伊可新”广泛的影响力,构建了“伊可新”儿童营养品、儿童健康食品、儿童健康用品等儿童健康产品系列。
Main Business 环保、医药和电子信息产品的生产销售
Legal Representative 朱效平
Top Executives
董事长:朱效平
副董事长:杨杰
董事:方宁,朱效平,程树仓,张大钰,沈宝杰
独立董事:杜宁,张志元,吕玉芹
Top 5 Shareholder
Shareholder name Nature Holding Date
山东华特控股集团有限公司流通A股22.00%30/09/2024
香港中央结算有限公司流通A股5.20%30/09/2024
郭伟松流通A股4.95%30/09/2024
尹俊涛流通A股3.52%30/09/2024
汇添富基金管理股份有限公司-社保基金17022组合流通A股3.06%30/09/2024
Company Secretary 范智胜
Solicitors 济南大千律师事务所
Auditors 山东正源会计师事务所有限公司
Tel No 0531-85198606;0531-85198601
Fax No 0531-85198602
Website www.sd-wit.com
Email wit@sd-wit.com;fzs@sd-wit.com;tbo@sd-wit.com;wangcy@sd-wit.com
Company Address
Register: 山东省临沂市沂南县县城振兴路6号
Office: 山东省济南市经十路17703号华特广场A403
Listing Date 09/06/1999
Shares Capital
Shares Capital: 234,331,485
Total A Share: 234,331,485
Listed A Share: 234,207,235
Non-tradable A Share: 124,250
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 2.500
DPS(RMB)* ¥ 2.000
NBV Per Share(RMB)* ¥ 12.725
Market Capitalization(RMB) 6.031B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.